Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03180034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03180034 · ClinicalTrials.gov record · last posted 2025-09-04

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Study acronym: ESCUDDO
StatusActive, Not Recruiting
PhasePhase 4
Started2017-11-29
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer. Vaccines that protect against infection with these types of human papillomavirus may reduce the risk of cervical cancer. Both Gardasil-9 and Cervarix protect against HPV 16 and 18, which cause 70% of all cervical cancers. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer. HPV vaccines are expensive-many countries cannot afford them-more than one dose is needed, and giving multiple doses is difficult. Researchers want to find out if one dose prevents HPV infection. If it does, more people might get the vaccine.

Amendment record 445 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 445 times since 2017-06-07; most recent amendment 2025-09-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-11-23
Status change Enrolling by Invitation→Active, Not Recruitingv435
2022-08-11
Status change Active, Not Recruiting→Enrolling by Invitationv429
2020-12-08
Status change Completed→Active, Not Recruitingv422
2020-10-19
Status change Active, Not Recruiting→Completedv421
2020-04-02
Status change Recruiting→Active, Not Recruitingv420
2018-01-04
Status change Not Yet Recruiting→Recruitingv108
Trial Details
NCT Number NCT03180034
Lead Sponsor National Cancer Institute (NCI)
Collaborators: Bill and Melinda Gates Foundation
Conditions Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
Enrollment 27,945 participants
Start Date 2017-11-29
Primary Completion 2025-08-21 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-04